Ekso Bionics Stock Price, News & Analysis (NASDAQ:EKSO) $1.56 -0.10 (-6.02%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$1.56▼$1.6850-Day Range$0.68▼$1.7552-Week Range$0.62▼$1.88Volume54,856 shsAverage Volume45,774 shsMarket Capitalization$22.20 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Ekso Bionics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside476.9% Upside$9.00 Price TargetShort InterestHealthy0.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.29) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector570th out of 957 stocksGeneral Industrial Machinery, Industry6th out of 8 stocks 3.5 Analyst's Opinion Consensus RatingEkso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Ekso Bionics has a forecasted upside of 476.9% from its current price of $1.56.Amount of Analyst CoverageEkso Bionics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.61% of the float of Ekso Bionics has been sold short.Short Interest Ratio / Days to CoverEkso Bionics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ekso Bionics has recently increased by 109.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEkso Bionics does not currently pay a dividend.Dividend GrowthEkso Bionics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EKSO. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Ekso Bionics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for EKSO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Ekso Bionics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ekso Bionics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Ekso Bionics is held by insiders.Percentage Held by InstitutionsOnly 9.54% of the stock of Ekso Bionics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ekso Bionics are expected to grow in the coming year, from ($1.29) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ekso Bionics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ekso Bionics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEkso Bionics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ekso Bionics Stock (NASDAQ:EKSO)Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therap, an adjustable and lower-limb powered exoskeleton; and Ekso Indego Personal, a powered lower limb orthosis. It has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in San Rafael, California.Read More EKSO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EKSO Stock News HeadlinesDecember 3, 2023 | americanbankingnews.comEkso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.comNovember 16, 2023 | finance.yahoo.comEkso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29December 7, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 2, 2023 | finance.yahoo.comCenters for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego PersonalOctober 27, 2023 | finanznachrichten.deEkso Bionics Holdings, Inc.: Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38%October 27, 2023 | finance.yahoo.comQ3 2023 Ekso Bionics Holdings Inc Earnings CallOctober 27, 2023 | finance.yahoo.comEkso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2023 Earnings Call TranscriptOctober 26, 2023 | seekingalpha.comEkso Bionics Holdings, Inc. (EKSO) Q3 2023 Earnings Call TranscriptDecember 7, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 26, 2023 | msn.comEkso Bionics Holdings GAAP EPS of -$0.24, revenue of $4.6MOctober 26, 2023 | finance.yahoo.comEkso Bionics Reports Third Quarter 2023 Revenue Growth of 38%October 25, 2023 | msn.comEkso Bionics Holdings Q3 Earnings PreviewOctober 19, 2023 | finance.yahoo.comEkso Bionics to Report Third Quarter 2023 Financial Results on October 26, 2023September 27, 2023 | finance.yahoo.comEkso Bionics Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Include Personal Exoskeletons within a Medicare Benefit CategorySeptember 22, 2023 | seekingalpha.comEKSO Ekso Bionics Holdings, Inc.September 11, 2023 | finance.yahoo.comEkso Bionics to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 9, 2023 | benzinga.comEkso Bionics Holdings Stock (NASDAQ:EKSO) Dividends: History, Yield and DatesAugust 25, 2023 | benzinga.comBionic Devices market is projected to grow at a CAGR of 9.5% by 2033: VisiongainJuly 28, 2023 | seekingalpha.comEkso Bionics Holdings, Inc. (EKSO) Q2 2023 Earnings Call TranscriptJuly 28, 2023 | finanznachrichten.deEkso Bionics Holdings, Inc.: Ekso Bionics Reports Record Revenues of $4.7 Million in Second Quarter 2023July 28, 2023 | msn.comEkso Bionics Holdings GAAP EPS of -$0.31 misses by $0.03, revenue of $4.7M beats by $0.35MJuly 28, 2023 | finance.yahoo.comEkso Bionics Reports Record Revenues of $4.7 Million in Second Quarter 2023July 28, 2023 | finance.yahoo.comQ2 2023 Ekso Bionics Holdings Inc Earnings CallJuly 20, 2023 | finance.yahoo.comEkso Bionics to Report Second Quarter 2023 Financial Results on July 27, 2023July 14, 2023 | au.finance.yahoo.comEKSO - Ekso Bionics Holdings, Inc.May 15, 2023 | marketwatch.comHealthcare Assistive Robot Market Expected Growth, Demand and Trends for 2030 | Barrett Technology, Cyberdyne, Ekso BionicsMay 11, 2023 | marketwatch.comHuman Augmentation Market Report Covers Future Trends with Research 2023-2029 | B-Temia, BrainGate, Ekso BionicsSee More Headlines Receive EKSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/26/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry General industrial machinery, Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EKSO Previous SymbolOTCMKTS:EKSOD CUSIPN/A CIK1549084 Webwww.eksobionics.com Phone(510) 984-1761Fax510-927-2647Employees72Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+476.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,080,000.00 Net Margins-89.28% Pretax Margin-89.28% Return on Equity-76.01% Return on Assets-42.36% Debt Debt-to-Equity Ratio0.33 Current Ratio2.85 Quick Ratio2.15 Sales & Book Value Annual Sales$12.91 million Price / Sales1.72 Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book0.80Miscellaneous Outstanding Shares14,230,000Free Float13,167,000Market Cap$22.20 million OptionableNot Optionable Beta1.87 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Scott G. Davis (Age 53)CEO & Director Comp: $535.8kMr. Jerome Wong (Age 49)Corporate Controller, Corporate Secretary & CFO Comp: $356.81kMr. Jason C. JonesChief Operating OfficerMs. Rachael AndersonGlobal Director of Marketing & Strategic GrowthMr. Anthony PrattVice President of SalesMs. Ann CooksonHuman Resources DirectorMs. Foon Lim ChweePresident of APACMr. Stephan AderholdSenior VP & GM of EMEAMore ExecutivesKey CompetitorsPurple BiotechNASDAQ:PPBTCumberland PharmaceuticalsNASDAQ:CPIXSynlogicNASDAQ:SYBXFortress BiotechNASDAQ:FBIOElevation OncologyNASDAQ:ELEVView All CompetitorsInsiders & InstitutionsEssex Investment Management Co. LLCSold 234,089 shares on 11/9/2023Ownership: 1.550%Strategic Wealth Investment Group LLCBought 8,752 shares on 11/4/2023Ownership: 0.300%Scott G DavisSold 37,446 sharesTotal: $37,446.00 ($1.00/share)Jerome WongSold 12,784 sharesTotal: $12,784.00 ($1.00/share)Steven ShermanSold 45,660 sharesTotal: $65,750.40 ($1.44/share)View All Insider TransactionsView All Institutional Transactions EKSO Stock Analysis - Frequently Asked Questions Should I buy or sell Ekso Bionics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EKSO shares. View EKSO analyst ratings or view top-rated stocks. What is Ekso Bionics' stock price target for 2024? 1 equities research analysts have issued twelve-month price targets for Ekso Bionics' stock. Their EKSO share price targets range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 476.9% from the stock's current price. View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts. How have EKSO shares performed in 2023? Ekso Bionics' stock was trading at $1.19 at the beginning of the year. Since then, EKSO stock has increased by 31.1% and is now trading at $1.56. View the best growth stocks for 2023 here. Are investors shorting Ekso Bionics? Ekso Bionics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 71,100 shares, an increase of 109.7% from the October 31st total of 33,900 shares. Based on an average daily trading volume, of 69,800 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.6% of the company's shares are short sold. View Ekso Bionics' Short Interest. When is Ekso Bionics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our EKSO earnings forecast. How were Ekso Bionics' earnings last quarter? Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) announced its quarterly earnings data on Thursday, October, 26th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.07. The firm earned $4.61 million during the quarter, compared to the consensus estimate of $4.53 million. Ekso Bionics had a negative net margin of 89.28% and a negative trailing twelve-month return on equity of 76.01%. When did Ekso Bionics' stock split? Ekso Bionics shares reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Ekso Bionics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include Organigram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA). Who are Ekso Bionics' major shareholders? Ekso Bionics' stock is owned by a number of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (1.55%), Strategic Wealth Investment Group LLC (0.30%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman. View institutional ownership trends. How do I buy shares of Ekso Bionics? Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:EKSO) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ekso Bionics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.